Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.
- 2025-02-18
- Theranostics 15(8)
- Guangze Sang
- Bingkai Wang
- Yujie Xie
- Yu Chen
- Feng Yang
- PubMed: 40093907
- DOI: 10.7150/thno.103983
Inflammatory bowel disease (IBD) is a chronic condition affecting the intestines, marked by immune-mediated inflammation. This disease is known for its recurrent nature and the challenges it presents in treatment. Recently, probiotic have gained attention as a promising alternative to traditional small molecular drugs and monoclonal antibody chemotherapies for IBD. Probiotic, recognized as a "living" therapeutic agent, offers targeted treatment with minimal side effects and the flexibility for biological modifications, making them highly effective for IBD management. This comprehensive review presents the latest advancements in engineering probiotic-based materials, ranging from basic treatment mechanisms to the modification techniques used in IBD management. It delves deep into how probiotic produces therapeutic effects in the intestinal environment and discusses various strategies to enhance probiotic's efficacy, including genetic modifications and formulation improvements. Additionally, the review addresses the challenges, practical application conditions, and future research directions of probiotic-based therapies in IBD treatment, providing insights into their feasibility and potential clinical implications.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Lactobacillus salivarius UCC118 | Reduced Inflammatory Bowel Disease Symptoms | Beneficial | Moderate |
| Lactobacillus salivarius UCC118 | Reduced Intestinal Inflammation | Beneficial | Moderate |
| Lactobacillus salivarius UCC118 | Reduced Risk of Colorectal Cancer | Beneficial | Moderate |